(DDM) — Demand is rapidly rising across Nigeria for Lenacapavir, a newly introduced injectable drug designed to prevent Human Immunodeficiency Virus infection, as anticipation builds ahead of its nationwide rollout.
Health sources indicate that many Nigerians are already making inquiries and seeking access to the drug, driven by growing awareness of its effectiveness and convenience compared to traditional daily preventive medications.
Lenacapavir, administered as a long-acting injection, is expected to provide extended protection against HIV, reducing the need for frequent dosing and improving adherence among users.
Medical experts say the innovation represents a significant breakthrough in HIV prevention, particularly for individuals at higher risk of exposure, including key populations and healthcare workers.
Public health advocates note that Nigeria, which carries a substantial burden of HIV cases, stands to benefit greatly from improved prevention tools that can help reduce new infections.
The surge in demand has, however, raised concerns about availability, distribution logistics, and equitable access once the drug is officially rolled out nationwide.
Officials within the health sector are reportedly working on frameworks to ensure that the injection is distributed efficiently, prioritising those most in need while avoiding shortages.
Experts also stress the importance of proper medical guidance, noting that the injection should be administered under professional supervision as part of a broader HIV prevention strategy.
In addition to the injection, they recommend continued use of other preventive measures such as testing, safe practices, and public awareness campaigns.
Some Nigerians have expressed optimism about the development, describing it as a potential game-changer in the fight against HIV/AIDS in the country.
Others, however, have raised concerns about affordability and whether the treatment will be accessible to low-income populations once it becomes widely available.
Global health organisations have previously highlighted the importance of introducing long-acting preventive options like Lenacapavir in countries with high HIV prevalence, citing their potential to significantly reduce transmission rates.
As preparations for the rollout continue, stakeholders are calling for strong government support, funding, and public education to maximise the impact of the new intervention.
The coming months are expected to be critical in determining how effectively Nigeria can integrate this breakthrough into its national HIV prevention strategy.
